Neogen Beat Earnings Estimates. Its Animal Safety Business Is Still Broken.

The two-segment story

Neogen's Food Safety segment, which accounts for roughly 74 percent of total revenue, delivered $156.7 million in the quarter, up 2.6 percent year over year. Core Food Safety growth (which strips out currency effects and divestitures) was 4.0 percent, driven by an 11 percent increase in Indicator Testing and Culture Media and a 5.5 percent gain in Bacterial and General Sanitation. CEO Mike Nassif called the segment's performance evidence that the company is "well positioned for continued fundamental improvement across the organization."

Animal Safety told a different story. The segment posted $54.5 million in revenue, a 20.1 percent decline from the prior year. Core Animal Safety revenue fell 8.7 percent. The culprit: third-party supplier disruptions that caused backorders, quality problems, and inventory write-offs. Nassif described the issues as "transient" and said the company is "actively engaged in improving these production-related challenges through our supplier qualification and sales and operations planning process."

The word "transient" is doing considerable work in that sentence. Biosecurity products within Animal Safety fell 37 percent. Animal Care and Other dropped 43.3 percent. These are not rounding errors.

Margins held, barely

GAAP gross margin declined to 46.9 percent from 49.9 percent a year ago, weighed down by duplicative costs from the ongoing Petrifilm manufacturing transition (the in-house production of 3M's legacy indicator testing product), tariff-related expenses, and inventory write-offs tied to the supplier problems. But adjusted gross margin actually ticked up to 51.7 percent from 51.4 percent, and adjusted EBITDA margin expanded sequentially by 110 basis points to 22.8 percent.

The GAAP bottom line was a net loss of $17.0 million, or $(0.08) per diluted share. That compares to a net loss of $10.9 million in the year-ago quarter. The gap between the GAAP loss and the adjusted earnings of $0.09 per share reflects the ongoing integration costs from the 2022 merger with 3M's Food Safety Division, a $5.3 billion transaction that has dominated Neogen's financial narrative for three years.

Strategic moves: genomics sale and Petrifilm

Two developments are reshaping the company's balance sheet and operating model. First, Neogen announced the sale of its global genomics business to Zoetis for $160 million (approximately $140 million net of transaction costs). The proceeds will be used to pay down debt, with management targeting a net debt-to-adjusted EBITDA ratio below three times by the end of calendar year 2026. The deal is expected to close in the second quarter of fiscal 2027.

Second, the Petrifilm manufacturing transition, the final major integration milestone from the 3M deal, remains on track for completion in November of fiscal 2027. The company has initiated operational and performance validation on multiple SKUs and is adding an R&D pilot line to enable custom products and higher incremental margins as volumes scale. This is the piece of the 3M integration that, if executed well, should unlock the margin expansion thesis that originally justified the merger.

To be sure, Neogen has been promising margin improvement from the 3M integration for over three years, and the timeline has slipped before. But the sequential EBITDA margin improvement in the third quarter and the approaching Petrifilm milestone suggest the company is closer to the finish line than it has been at any point since the deal closed.

Guidance: raised on revenue, held on EBITDA

Management raised its fiscal year 2026 revenue outlook to $857 million to $860 million (up from a prior range that implied roughly $850 million), while maintaining adjusted EBITDA guidance of $175 million. The revenue raise reflects the Food Safety strength; the flat EBITDA guidance reflects the supplier headwinds, elevated freight costs (approximately $1.5 million per quarter), and foreign exchange pressure.

The conservative EBITDA hold is likely what kept the stock from rallying on the earnings beat. Investors who bought the 45 percent year-to-date run were looking for evidence that the operational turnaround was accelerating. They got a mixed signal: Food Safety is working, but Animal Safety is not, and management is not yet willing to raise the profitability bar.

Why the stock didn't move

The flat reaction makes more sense in context. Neogen's stock had already more than doubled from its 52-week low of $3.87, reached in mid-2025 after a $612 million goodwill impairment charge related to the 3M acquisition cratered the fourth-quarter 2025 results. The rally from that trough priced in a significant recovery. Thursday's results confirmed the recovery is happening in Food Safety but revealed a new problem in Animal Safety that was not widely anticipated.

Analysts covering the stock hold a consensus rating of Hold, with a median price target of approximately $11. At $10.16, the stock trades roughly 8 percent below that target. Piper Sandler maintained a Neutral rating with a $10 price target in January; Guggenheim maintained a Buy with a $12 target. The analyst community, like the stock price itself, appears to be waiting for the Animal Safety segment to stabilize before turning more constructive.

The Petrifilm transition, the genomics divestiture, and the supplier qualification overhaul all point toward a cleaner, more focused Neogen by mid-2027. But the company's recent history (a $5.3 billion merger that produced a $1 billion goodwill write-down, persistent integration delays, and now third-party supplier failures) suggests that execution risk remains the dominant variable. Only time will tell whether the third quarter's earnings beat marks the beginning of sustained improvement or another false start in a turnaround that has tested investors' patience for three years.